Sweden · Biotechnology startup
Sweden · Cantargia
Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.
Funding reportedLast round: Post ipo equity
What company datasets say Cantargia raised
Funding, as reported
Reported in all257Min the source's currency
Rounds2
Last roundPost ipo equity
Last round dateJun 2022
Investors listed2
Biotechnology in Sweden
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Cantargia in front of investors. Or tell us what we have wrong.